Share Price, page-234

. Not for me. ACAD have done a great job running the trials but have proved hopeless at running their company.

I don’t want them anywhere near my money. They had the opportunity to buy us for peanuts when they had an US$8 Bn MC. They didn’t even see the opportunity.

And further , as today’s post with comments from Karst Peak stated, that on current cash flow projections this is conservatively valued at AU$1bn . That’s just on Retts cashflow for North America. Add at least AU$1bn for ROW. Jon Pilcher has again stated yesterday they will start evaluating their options now..

So a conservative valuation is probably in excess of $16 per share. I posted a year a year ago this was worth $15 and got screamed at by angry posters declaring it was not worth more than $5. We will see.

That’s not attributing and value to FXS or NNZ-2591.

It’s still very undervalued and could easily stay they way for many months. ASX investors just don’t understand or buy into Biotechs , but the Karst Peaks of the world do.

AVH languished for many months after FDA approvals. Karst Peak bought a significant stake at .05. It went to .85 about 6 months later. Karst Peak killed the pig on that trade..And they will repeat that sort of percentage gain here.

This is the best time ever to buy. It’s really undervalued a d derisked. It’s free money.